NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

511.70 6.10 (1.21%)

29.03% Fall from 52W High

1.2M NSE+BSE Volume

NSE 19 May, 2025 3:31 PM (IST)

12,411

Market Cap

High in industry

1.1

Beta 1Year

High Volatility

Board Meeting

The next board meeting for Granules India Ltd. is on 28 May 2025 for the purpose of Audited Results & Final Dividend See details

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Granules India Ltd.

22 Oct 2020

511.70

1.21%

Granules India

Buy: Granules India Ltd.

Target

KRChoksey

Granules India Ltd. is trading above its 50 day SMA of 475.3

Granules India Ltd.

22 Oct 2020

511.70

1.21%

GRANULES INDIA

Accumulate: Granules India Ltd.

Recommendation Target

Geojit BNP Paribas

Granules India Ltd. is trading below its 100 day SMA of 520.6

Granules India Ltd.

21 Oct 2020

511.70

1.21%

Granules lndia

Buy: Granules India Ltd.

Target

ICICI Securities Limited

Granules India Ltd. is trading below its 100 day SMA of 520.6

Granules India Ltd.

21 Oct 2020

511.70

1.21%

BP Equities Granules India Ltd Q2FY21 Result Update

Buy: Granules India Ltd.

Target

BP Wealth

Granules India Ltd. is trading above its 50 day SMA of 475.3

Granules India Ltd.

21 Oct 2020

511.70

1.21%

Granules India

Buy: Granules India Ltd.

Sharekhan

Granules India Ltd. has gained 16.06% in the last 1 Week

Granules India Ltd.

20 Oct 2020

511.70

1.21%

Making strong headway

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India Ltd. is trading above its 50 day SMA of 475.3

Granules India Ltd.

15 Sep 2020

511.70

1.21%

Granules lndia

Buy: Granules India Ltd.

ICICI Securities Limited

Granules India Ltd. is trading below its 100 day SMA of 520.6

Granules India Ltd.

11 Sep 2020

511.70

1.21%

Commercial benefits from complex products underway

Buy: Granules India Ltd.

Target

Motilal Oswal

With the generic version of Focalin XR being approved, GRAN now has 30 ANDA approvals (28 final and 2 tentative). It is used for the treatment of Focalin XR and its generic equivalent had US sales of USD556m for 12- There are 5 companies having final approval for this product, other than GRAN. Accordingly, we expect price erosion of 7-10% with market share gradually building up to 10% over 12 months post the launch of the product. This could provide meaningful upside to GRANs ANDA-led Formulations GRAN has multiple growth levers, such as (a) the ANDA pipeline for US generics (with some products having limited competition opportunity), which should drive an increase in the share of formulations for developed markets, (b) enhanced reach for core molecules, and (c) reduced opex through backward integration.

Granules India Ltd. is trading below its 100 day SMA of 520.6

Granules India Ltd.

20 Jul 2020

511.70

1.21%

BP Equities Granules India Ltd Q1FY21 Result Update

Buy: Granules India Ltd.

Recommendation Target

BP Wealth

Granules (GIL) posted revenues of INR 7,356mn with 23.6% YoY growth, which was ~6% above our estimate of INR 6929mn. Revenue growth was mainly driven by new product launches and an increase in market share of existing products. Gross margin improved (918bps YoY) due to higher formulation sales (52% of revenue vs 48% in Q1FY20). Subsequently, EBITDA margin expanded by 503bps to 25% level was 475bps higher than our estimate. EBITDA was partially impacted by one-off INR 280mn related to metformin recall (INR150mn) and COVID-19 related expenses (INR130mn). As per management EBITDA margin can be sustainable (~23% for FY21) as continued traction in the formulation business. GIL reported PAT of INR 1114mn, was above our estimate of INR 744mn driven by strong operational performance and lower tax rate (25.3% vs 32% in Q1FY20). Management expects to achieve 30% PAT growth in FY21 compared previous year and 25% for FY22 given the strong traction in base business along with new product launches in the US generics business. Post...

Granules India Ltd. has gained 16.06% in the last 1 Week

Granules India Ltd.

20 Jul 2020

511.70

1.21%

GRANULES INDIA

Buy: Granules India Ltd.

Target

Geojit BNP Paribas

Granules achieved its highest ever quarterly revenue of Rs.736cr during Q1FY21 with a YoY growth of 24%. The Finished Dosages segment grew by 35% during the quarter as the company successfully launched Colchicine tablets and Butalbital APAP caffeine tablets in the U.S The company reduced its Promoter pledge percentage from 37.6% to 8.7% through the recent buyback process. We expect net profit to grow at a CAGR of 22% over FY20-FY22E on...

Granules India Ltd. has an average target of 682.00 from 5 brokers.

Is Granules India Ltd. worth buying?

859 Votes:

Buy 84.05%

Sell 10.24%

Hold 5.7%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf